Top

American Journal of Cardiovascular Drugs

Published in:

01-12-2015 | Review Article

Hypercholesterolemia and Hypertension: Two Sides of the Same Coin

Authors: Branislava Ivanovic, Marijana Tadic

Published in: American Journal of Cardiovascular Drugs | Issue 6/2015

Abstract

The aim of this review article is to summarize the current knowledge about mechanisms that connect blood pressure regulation and hypercholesterolemia, the mutual interaction between hypertension and hypercholesterolemia, and their influence on atherosclerosis development. Our research shows that at least one-third of the population of Western Europe has hypertension and hypercholesterolemia. Several biohumoral mechanisms could explain the relationship between hypertension and hypercholesterolemia and the association between these risk factors and accelerated atherosclerosis. The most investigated mechanisms are the renin-angiotensin-aldosterone system, oxidative stress, endothelial dysfunction, and increased production of endothelin-1. Arterial hypertension is frequently observed in combination with hypercholesterolemia, and this is related to accelerated atherosclerosis. Understanding the mechanisms behind this relationship could help explain the benefits of therapy that simultaneously reduce blood pressure and cholesterol levels.

Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nat Health. 1957;47:4–24.CrossRef

Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Int Med. 1961;55:33–50.CrossRefPubMed

Tunstall-Pedoe H, Chen R, Kramarz P. Prevalence of individuals with both raised blood pressure and raised cholesterol in WHO MONICA Project population surveys 1989–97. Pharmacoepidemiol Drug Saf. 2004;13(Suppl 1):S307–8.

Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14:83–90.CrossRefPubMed

Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010. Circulation. 2013;128(1):29–41.CrossRefPubMedCentralPubMed

Williams B, Wilson K, Lacey L, et al. The prevalence and management of patients with co-existing hypertension and hypercholesterolaemia in the UK. Eur Heart J. 2004;25:528–9.CrossRef

Spasito AC. Emerging insights into hypertension and dyslipidaemia synergies. Eur Heart J Suppl. 2004;6 (Supplement G):G8–12.CrossRef

Kurtel H, Rodrigues SF, Yilmaz CE, Yildirim A, Granger DN. Impaired vasomotor function induced by the combination of hypertension and hypercholesterolemia. J Am Soc Hypertens. 2013;7(1):14–23.CrossRefPubMedCentralPubMed

González J, Valls N, Brito R, Rodrigo R. Essential hypertension and oxidative stress: new insights. World J Cardiol. 2014;6(6):353–66.CrossRefPubMedCentralPubMed

10.

Kalayci R, Kaya M, Uzun H, Bilgic B, Ahishali B, Arican N, Elmas I, Küçük M. Influence of hypercholesterolemia and hypertension on the integrity of the blood-brain barrier in rats. Int J Neurosci. 2009;119(10):1881–904.CrossRefPubMed

11.

John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Current Hypertens Rep. 2003;5:199–207.CrossRef

12.

Alexandru N, Popov D, Dragan E, Andrei E, Georgescu A. Circulating endothelial progenitor cell and platelet microparticle impact on platelet activation in hypertension associated with hypercholesterolemia. PLoS One. 2013;8(1):e52058.CrossRefPubMedCentralPubMed

13.

Rodrigues SF, Almeida-Paula LD, Granger DN. Synergistic effects of high blood cholesterol and hypertension on leukocyte and platelet recruitment in the cerebral microcirculation. Hypertension. 2014;63(4):747–52.CrossRefPubMedCentralPubMed

14.

Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4–18.CrossRefPubMed

15.

Böger RH, Bode-Böger SM, Szuba A, et al. Asymetric Dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction—its role in hypercholesterolemia. Circulation. 1998;98:1842–7.CrossRefPubMed

16.

Päivä H, Laakso J, Laine H, et al. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:1241–7.CrossRefPubMed

17.

Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ Res. 1994;74:1141–8.CrossRefPubMed

18.

Drapala A, Sikora M, Ufnal M. Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins. J Renin Angiotensin Aldosterone Syst. 2014;15(3):250–8.CrossRefPubMed

19.

Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation. 1997;96:3264–5.PubMed

20.

Daugherty A, Lu H, Rateri DL, Cassis LA. Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol. 2008;3(6):625–36.CrossRefPubMedCentralPubMed

21.

Borghi C, Veronesi M, Cosentino E, Cicero AF, Kuria F, Dormi A, Ambrosioni E. Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. J Hypertens. 2007;25(10):2051–7.CrossRefPubMed

22.

Warnholtz A, Nickenig G, Schulz E, et al. Increased NADHoxidase-mediated superoxide production in the early stages of atherosclerosis:evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027–33.CrossRefPubMed

23.

Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756–67.CrossRefPubMed

24.

Matsunaga T, Hokari S, Koyama I, Harada T, Komoda T. NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun. 2003;303(1):313–9.CrossRefPubMed

25.

Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin converting enzyme inhibition prevents arterial NF-kB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532–41.CrossRefPubMed

26.

Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556–62.CrossRefPubMed

27.

Alva F, Samanego V, Gonzalez V, Mogler R, Aney E. Structural and dynamic changes in the elastic arteries due to arterial hypertension and hypercholesterolemia. Clin Cardiol. 1993;16:614–8.CrossRefPubMed

28.

Dobsak P, Soska V, Sochor O, Jarkovsky J, Novakova M, Homolka M, Soucek M, Palanova P, Lopez-Jimenez F, Shirai K. Increased cardio-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb. 2015;22(3):272–83.CrossRefPubMed

29.

Kanaki AI, Sarafidis PA, Georgianos PI, Kanavos K, Tziolas IM, Zebekakis PE, Lasaridis AN. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013;26(5):608–16.CrossRefPubMed

30.

Saba PS, Roman MJ, Longhini C, Scorzoni D, Pini R, Devereux RB, Ganau A. Carotid intimal-medial thickness and stiffness are not affected by hypercholesterolemia in uncomplicated essential hypertension. Arterioscler Thromb Vasc Biol. 1999;19(11):2788–94.CrossRefPubMed

31.

Riggio S, Mandraffino G, Sardo MA, Iudicello R, Camarda N, Imbalzano E, Alibrandi A, Saitta C, Carerj S, Arrigo T, Saitta A. Pulse wave velocity and augmentation index, but not intima-media thickness, are early indicators of vascular damage in hypercholesterolemic children. Eur J Clin Invest. 2010;40(3):250–7.CrossRefPubMed

32.

Laurent S, Hayoz D, Trazzi S, Boutouyrie P, Waeber B, Omboni S, Brunner HR, Mancia G, Safar M. Isobaric compliance of the radial artery is increased in patients with essential hypertension. J Hypertens. 1993;11:89–98.CrossRefPubMed

33.

Cernes R, Zimlichman R, Shargorodsky M. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Adv Cardiol. 2008;45:65–81.CrossRefPubMed

34.

Hayoz D, Weber R, Rutschmann B, Darioli R, Burnier M, Waeber B, Brunner HR. Post-ischemic blood flow response in hypercholesterolemic patients. Hypertension. 1995;26:497–502.CrossRefPubMed

35.

Giannattasio C, Mangoni A, Failla M, Stella M, Carugo S, Bombelli M, Sega R, Mancia G. Combined effects of hypertension and hypercholesterolemia on radial artery function. Hypertension. 1997;29:583–6.CrossRefPubMed

36.

Sharman JE, McEniery CM, Dhakam ZR, Coombes JS, Wilkinson IB, Cockcroft JR. Pulse pressure amplification during exercise is significantly reduced with age and hypercholesterolemia. J Hypertens. 2007;25(6):1249–54.CrossRefPubMed

37.

Versari D, Gossl M, Mannheim D, Daghini E, Galili O, Napoli C, Lerman L, Lerman A. Hypertension and hypercholesterolemia differentially affect the function and structure of pig carotid artery. Hypertension. 2007;50:1063–8.CrossRefPubMed

38.

Georgescu A, Alexandru N, Andrei E, Titorencu I, Dragan E, Tarziu C, Ghiorghe S, Badila E, Bartos D, Popov D. Circulating microparticles and endothelial progenitor cells in atherosclerosis; pharmacological effects of irbesartan. J Thromb Haemost. 2012;10:680–91.CrossRefPubMed

39.

Toikka JO, Laine H, Ahotupa M, Haapanen A, Viikari JSA, Hartiala JJ, Raitakari OT. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension. 2000;36:929–36.CrossRefPubMed

40.

Klima Ł, Kawecka-Jaszcz K, Stolarz-Skrzypek K, Menne J, Fijorek K, Olszanecka A, Wojciechowska W, Bilo G, Czarnecka D. Structure and function of large arteries in hypertension in relation to oxidative stress markers. Kardiol Pol. 2013;71(9):917–23.CrossRefPubMed

41.

Rodriguez-Porcel M, Lerman LO, Herrmann J, Sawamura T, Napoli C, Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol. 2003;23(5):885–91.CrossRefPubMed

42.

Rodriguez-Porcel M, Lerman A, Herrmann J, Schwartz RS, Sawamura T, Condorelli M, Napoli C, Lerman LO. Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature. Cardiovasc Res. 2003;58(1):213–21.CrossRefPubMed

43.

Herrmann J, Samee S, Chade A, Porcel MR, Lerman LO, Lerman A. Differential effect of experimental hypertension and hypercholesterolemia on adventitial remodeling. Arterioscler Thromb Vasc Biol. 2005;25:447–53.CrossRefPubMed

44.

Seo YH, Lee CS, Yuk HB, Yang DJ, Park HW, Kim KH, Kim WH, Kwon TG, Bae JH. Hypercholesterolemia and in-vivo coronary plaque composition in patients with coronary artery disease: a virtual histology - intravascular ultrasound study. Korean Circ J. 2013;43(1):23–8.CrossRefPubMedCentralPubMed

45.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285–95.CrossRefPubMed

46.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk–overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2305–14.CrossRefPubMed

47.

Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2015;1:CD008170.PubMed

48.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174000 participants in 27 randomised trials. Lancet. 2015 Jan 8. pii: S0140-6736(14)61368-4.

49.

Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Elisaf M, GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004;18(11):781–8.CrossRefPubMed

50.

Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R, JCAD Investigators. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J. 2007;71(12):1835–40.CrossRefPubMed

51.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.CrossRefPubMed

52.

Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS. Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol. 2011;9(6):647–57.CrossRefPubMed

53.

Williams HC, Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol. 2007;50:9–16.CrossRefPubMed

54.

Schiffrin EL, Deng LY. Comparison of effects of angiotensin I converting enzyme inhibition and ß-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension. 1995;25:699–703.CrossRefPubMed

55.

Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653–9.CrossRefPubMed

56.

Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22:1208–12.CrossRefPubMed

57.

Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905–10.CrossRefPubMed

58.

Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, et al. Distinct vascular and metabolic effects of different classes of antihypertensive drugs. Int J Cardiol. 2010;140:73–81.CrossRefPubMedCentralPubMed

59.

Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J. 2014;78(2):281–7.CrossRefPubMed

60.

Joo SJ. Anti-inflammatory effects of statins beyond cholesterol low- ering. Korean Circ J. 2012;42:592–4.CrossRefPubMedCentralPubMed

61.

Profumo E, Buttari B, Saso L, Rigano R. Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Curr Top Med Chem. 2014;14(22):2542–51.CrossRefPubMed

62.

Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol. 2014;10(2):140–7.CrossRefPubMedCentralPubMed

63.

Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100(21):2131–4.CrossRefPubMed

64.

Correale M, Abruzzese S, Greco CA, Concilio M, Biase MD, Brunetti ND. Pleiotropic effects of statin in therapy in heart failure: a review. Curr Vasc Pharmacol. 2014;12(6):873–84.CrossRefPubMed

65.

Tuñón J, Martín-Ventura JL, Blanco-Colio LM, Tarín N, Egido J. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vasc Health Risk Manag. 2007;3:521–6.PubMedCentralPubMed

66.

Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation l-type calcium channel antagonists ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155–67.CrossRefPubMed

67.

Ivanovic B, Tadic M. Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. J Cardiovasc Pharmacol Ther. 2013;18(6):544–9.CrossRefPubMed

68.

Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharm Des. 2014;20(40):6299–305.CrossRefPubMed

69.

Toblli JE, DiGennaro F, Giani JF, Dominici FP. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag. 2012;8:151–60.CrossRefPubMedCentralPubMed

70.

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45.

71.

Koh KK, Lim S, Choi H, Lee Y, Han SH, Lee K, Oh PC, Sakuma I, Shin EK, Quon MJ. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes. 2013;62(10):3547–52.CrossRefPubMedCentralPubMed

72.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1):3–16.CrossRefPubMed

73.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMed

74.

Ivanovic B, Tadic M. When does low normal blood pressure become too low? The J-curve phenomenon. Acta Cardiol. 2014;69(2):121–9.PubMed

75.

Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J. 2011;32(18):2247–55.CrossRefPubMed

76.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRef

77.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef

78.

Messerli FH, Pinto L, Tang SS, Thakker KM, Cappelleri JC, Sichrovsky T, Dubois RW. Impact of systemic hypertension on the cardiovascular benefits of statin therapy: a meta-analysis. Am J Cardiol. 2008;101(3):319–25.CrossRefPubMed

79.

Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, Pocock S, ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):907–13.CrossRefPubMed

80.

Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.CrossRefPubMed

81.

Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162(3):184–91.CrossRefPubMed

82.

Blood Pressure Lowering Treatment Trialists’ Collaboration1, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121–3.CrossRef

83.

Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.CrossRefPubMed

84.

Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. BMJ. 2003;326:1419e24.CrossRef

85.

Indian Polycap Study (TIPS), Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341–51.CrossRef

86.

Malekzadeh A. pilot double-blind randomized placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010;64:1220e7.CrossRef

87.

Lafeber M, Spiering W, van der Graaf Y, Nathoe H, Bots ML, Grobbee DE, Visseren FL. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. Am Heart J. 2013;166(2):282–9.CrossRefPubMed

88.

Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD:the UMPIRE randomized clinical trial. JAMA. 2013;310:918–29.CrossRefPubMed

89.

Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Rafter N, Tonkin A, Webster R, Billot L, Bompoint S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A; for the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–30. doi:10.1177/2047487314530382.

90.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.CrossRefPubMed

Title: Hypercholesterolemia and Hypertension: Two Sides of the Same Coin
Authors: Branislava Ivanovic
Marijana Tadic
Publication date: 01-12-2015
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 6/2015
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-015-0128-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hypercholesterolemia and Hypertension: Two Sides of the Same Coin

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry

Acknowledgement to Referees

Most Heart Failure Patients Die from Pump Failure: Implications for Therapy

Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses

Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses

Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page